Composition for promoting hair growth or preventing hair loss comprising biorenovation of formononetin as effective component

Abstract

The present invention relates to a composition for promoting hair growth or preventing hair loss containing a biotransformer of formononetin as an active ingredient. Since the biotransformer of formononetin of the present invention not only induces the proliferation of human dermal papilla cells but also has excellent effects in promoting the proliferation of skin cells and wound healing, it can be usefully used as a cosmetic composition, quasi-drug, pharmaceutical composition, or health functional food composition for promoting hair growth, preventing hair loss, or promoting hair growth.

Description

Technology Field

[0001] The present invention relates to a composition for promoting hair growth or preventing hair loss containing a biotransformation of formononetin as an active ingredient.

[0002] The present invention is the result of a project titled 'Development of Cosmeceutical Materials and Functional Care Products for Hair Loss Alleviation Using Bio-Renovation Technology' under the Regional Innovation Leading Enterprise Development Project funded by the Ministry of SMEs and Startups in 2025 (S3452042). Background Technology

[0003] The human body has approximately 100,000 to 150,000 hairs, and each hair has a different hair cycle in which it is generated, grows, and sheds by repeating the growth phase (anagen), regression phase (catagen), and resting phase (telogen). As a result, about 15% of the total hair is in the resting and regression phases, and an average of 50 to 100 hairs are normally shed and regenerated daily. This hair growth cycle repeats in a cycle of about 3 to 6 years.

[0004] Generally, hair loss refers to a condition where the growth phase of the hair cycle is shortened due to various causes, and the proportion of hair in the regression and resting phases becomes relatively higher, resulting in a greater-than-average number of hairs falling out. Causes of hair loss include the action of genetic androgen hormones, nutritional deficiencies caused by impaired local blood flow, autonomic nervous system disorders, autoimmune diseases, and endocrine disorders; however, the exact cause remains unknown to date. Finasteride, the most representative hair loss prevention agent, is a drug that inhibits the activity of 5α-reductase, an enzyme that produces dihydrotestosterone (DHT), a direct causative agent of hair loss. However, finasteride has drawbacks; it can cause fetal malformations in pregnant women, and side effects such as decreased libido, erectile dysfunction, and ejaculation disorders have been reported with long-term administration, requiring caution when taking the medication. In addition, widely used minoxidil-containing hair growth products are also approved by the FDA as over-the-counter drugs; however, they have drawbacks, such as being unsuitable for women and causing side effects like skin irritation, itching, redness, and worsening hair loss. Therefore, there is a need to develop a substance that is safe for both men and women, free from side effects, and effective in preventing hair loss and promoting hair growth.

[0005] The root portion where hair grows is called the hair bulb, and the indented area below it is called the hair dermal papilla. The hair dermal papilla is the most important part in hair development; it contains blood vessels and nerves, as well as dermal papilla cells, which supply nutrients to the hair matrix cells located directly above them to promote hair growth. The number of these dermal papilla cells is determined at birth, and as the number of cells decreases or they are lost, the number of hairs also decreases.

[0006] Meanwhile, biorenovation refers to a method of producing or manufacturing a desired product from a precursor by utilizing the enzymatic functions of microorganisms, and it is a general term for methods that induce structural changes in a substance through biological methods such as microbial fermentation or enzymatic treatment.

[0007] Regarding prior art related to hair or hair loss, Korean Registered Patent No. 2295754 discloses a "composition for strengthening hair roots, promoting hair growth, or preventing hair loss containing soybean germ extract," and Korean Registered Patent No. 1769402 discloses a "composition for promoting hair growth or preventing hair loss containing Aster extract." However, there has not yet been any disclosure regarding the "composition for promoting hair growth or preventing hair loss containing a biotransformed product of formononetin as an active ingredient" of the present invention. The problem to be solved

[0008] The present invention was derived from the above requirements, and the present invention provides a composition for promoting hair growth or preventing hair loss containing a biotransformer of formononetin as an active ingredient, and the present invention was completed by confirming that the biotransformer of formononetin of the present invention not only induces the proliferation of human dermal papilla cells but also has the effect of promoting the proliferation of skin cells and wound healing. means of solving the problem

[0009] To solve the above problem, the present invention provides a cosmetic composition for promoting hair growth or preventing hair loss containing a biotransformation of formononetin or a cosmetically acceptable salt thereof as an active ingredient.

[0010] In addition, the present invention provides a quasi-drug for promoting hair growth or preventing hair loss containing a biotransformation of formononetin or a pharmaceutically acceptable salt thereof as an active ingredient.

[0011] In addition, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth containing a biotransformation of formononetin or a pharmaceutically acceptable salt thereof as an active ingredient.

[0012] In addition, the present invention provides a health functional food composition for promoting hair growth or preventing hair loss, containing a biotransformation of formononetin or a food-grade salt thereof as an active ingredient. Effects of the invention

[0013] The present invention relates to a composition for promoting hair growth or preventing hair loss containing a biotransformer of formononetin as an active ingredient. The biotransformer of formononetin according to the present invention not only induces the proliferation of human dermal papilla cells but also has excellent effects in promoting the proliferation of skin cells and wound healing. Brief explanation of the drawing

[0014] Figure 1 shows the HPLC analysis results (A), conversion rate (B), and identification results (C) of formononetin biotransformers induced by biotransformation using various bacterial culture medium compositions. FM is formononetin, and FMP is formononetin-7-O-phosphate. Figure 2 shows the results of confirming the effect of formononetin biotransformers on inducing human dermal papilla cell proliferation. None is the untreated control group, MXD is the positive control group treated with minoxidil (25 μM), FM 12.5, 25 are the groups treated with formononetin at concentrations of 12.5 and 25 μM, and FMP 12.5, 25 are the groups treated with formononetin biotransformers at concentrations of 12.5 and 25 μM. * indicates that human dermal papilla cell proliferation in the minoxidil-treated group (MXD) or the formononetin biotransformer-treated group (FMP) increased statistically significantly compared to the untreated control group (None), with p<0.05. Figure 3 shows the results of confirming the regenerative effect of formononetin biotransformers on skin keratinocytes (HaCaT cells). None is the untreated control group, FM 12.5, 25 are groups treated with formononetin at concentrations of 12.5 and 25 μM, and FMP 12.5, 25 are groups treated with formononetin biotransformers at concentrations of 12.5 and 25 μM. Specific details for implementing the invention

[0015] To achieve the objective of the present invention, the present invention provides a cosmetic composition for promoting hair growth or preventing hair loss containing a biotransformation of formononetin or a cosmetically acceptable salt thereof as an active ingredient.

[0016] The “formononetin” of the present invention refers to 7-hydroxy-4’-methoxyisoflavone represented by the following chemical formula 1, and the “biotransformed product of formononetin” derived from formononetin through a biotransformation method is formononetin 7-O-phosphate (chemical formula 2), in which the phenolic hydroxyl group (-OH) at the 7th position of formononetin is substituted with a phosphate group (-OPO3H2).

[0017]

[0018]

[0019] The term "biological conversion method" of the present invention refers to a method of producing or manufacturing a compound by inducing structural changes, such as phosphorylation or glycosylation, from a substrate or precursor using microorganisms. Phosphorylation refers to the binding of a phosphoric acid group (HOPO(OH)O-) to a substrate by substituting a hydrogen atom of the substrate through the action of a kinase, and glycosylation refers to the addition of a glucoside, such as a monosaccharide or polysaccharide, to the substrate.

[0020] The biotransformed form of the above-mentioned formononetin is preferably

[0021] (1) Step of culturing microorganisms;

[0022] (2) a step of inducing a bioconversion reaction by adding formononetin to the microorganism cultured in step (1) above; and

[0023] (3) A step of freeze-drying and then grinding the formononetin biotransformation product obtained in step (2) above; but is not limited thereto.

[0024] The microorganism of step (1) above is preferably Bacillus siamensis ( Bacillus siamensis ) strain (accession number: KCTC 15908BP), but is not limited thereto.

[0025] The biotransformed form of the above-mentioned formononetin is even more preferably

[0026] (1) Bacillus siamensis ( Bacillus siamensis A step of culturing the strain in a medium containing 25–35 g / L glucose, 2–4 g / L tryptone, and 8–12 g / L yeast extract at 25–35℃ for 12–20 hours;

[0027] (2) a step of adding formononetin to the Bacillus siamensis strain cultured in step (1) above to induce a biotransformation reaction at 25–35°C for 60–80 hours; and

[0028] (3) A step of freeze-drying and then grinding the formononetin biotransformation product obtained in step (2) above; but is not limited thereto.

[0029] The biotransformed product of formononetin of the present invention or a cosmetically acceptable salt thereof may promote the growth of dermal papilla cells, but is not limited thereto.

[0030] In this specification, the term "acceptable salt" refers to any salt of a compound of the present invention that does not exhibit toxicity or is not unsuitable for food or pharmaceutical use while maintaining the biological properties of the compound of the present invention. Such salts may be derived from, and include, various organic and inorganic counterions known in the art. These salts include organic or inorganic acids, such as hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvate, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, chrysanthenic acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, Camponic acid, camphorsulfonic acid, 4-methylbicyclo [2.2.Acid addition salt formed with [2]-oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, cyclohexylsulfamic acid, quinic acid, or muconic acid, etc.; Or, it may include salts formed when an acidic proton present in the parent compound is substituted with a metal ion (e.g., alkali metal ion, alkaline earth metal ion, or aluminum ion), an alkali metal or alkaline earth metal hydroxide (e.g., sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide), or ammonia, or coordinately bonded with an organic base, such as an aliphatic, alicyclic, or aromatic organic amine, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucarmine, piperazine, tris(hydroxymethyl)-aminomethane, or tetramethylammonium hydroxide.

[0031] The cosmetic composition of the present invention includes, in addition to the active ingredient, ingredients commonly used in cosmetic compositions, such as fatty substances, organic solvents, solvents, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion chelating agents and chelating agents, preservatives, vitamins, blockers, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, conventional auxiliary agents such as lipid vesicles, and carriers.

[0032] The cosmetic composition of the present invention may be prepared in any formulation conventionally manufactured in the art, and may be prepared in, for example, as a hair tonic, hair conditioner, hair essence, hair lotion, hair nourishing lotion, hair shampoo, hair rinse, hair treatment, hair cream, hair nourishing cream, hair moisture cream, hair massage cream, hair wax, hair aerosol, hair pack, hair nourishing pack, hair soap, hair cleansing foam, hair drying agent, hair preservative, hair dye, hair wavy agent, hair bleaching agent, hair gel, hair glaze, hair dressing agent, hair lacquer, hair moisturizer, hair mousse, or hair spray, but is not limited thereto.

[0033] In addition, the present invention provides a quasi-drug for promoting hair growth or preventing hair loss containing a biotransformation of formononetin or a pharmaceutically acceptable salt thereof as an active ingredient.

[0034] The quasi-drug for preventing hair loss or promoting hair growth according to the present invention may be manufactured in the form of a cream, gel, patch, ointment, ointment, lotion, liquid, emulsion, powder, or spray, but is not limited thereto.

[0035] In the case where the formulation of the present invention is a cream or gel, animal fibers, plant fibers, wax, paraffin, starch, tracanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as carrier components.

[0036] In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0037] When the formulation of the present invention is a liquid or an emulsion, a solvent, a solvating agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0038] In addition, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth containing a biotransformation of formononetin or a pharmaceutically acceptable salt thereof as an active ingredient.

[0039] The pharmaceutical composition according to the present invention can be formulated and used in the form of oral formulations such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, external formulations, and sterile injectable solutions, respectively, according to conventional methods.

[0040] The pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.

[0041] Various compounds or mixtures that may be included as carriers, excipients, and diluents in the pharmaceutical composition of the present invention may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0042] When formulating, the formulation is prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, humectants, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules; these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin, with the above pharmaceutical composition. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. Witepsol, Macrogol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc. may be used as bases for suppositories.

[0043] Suitable dosages of the pharmaceutical composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, mode of administration, patient's age, body weight, sex, pathological condition, food, time of administration, route of administration, excretion rate, and response sensitivity.

[0044] The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by topical application to the skin, intravenous injection, subcutaneous injection, etc.

[0045] In addition, the present invention provides a health functional food composition for promoting hair growth or preventing hair loss, containing a biotransformation of formononetin or a food-grade salt thereof as an active ingredient.

[0046] The above health functional food composition may be manufactured in the form of powder, granules, pills, tablets, capsules, candy, syrup, or beverage, but is not limited thereto.

[0047] When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately used according to its purpose of use (prevention or improvement). Generally, when manufacturing food or beverages, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, relative to the raw material. However, in the case of long-term consumption for health purposes, the above amount may be less than the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range.

[0048] There are no special restrictions on the types of the above-mentioned health functional foods. Examples of foods to which the above-mentioned health functional food composition may be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea drinks, alcoholic beverages, and vitamin complexes, and include all health foods in the conventional sense.

[0049] In addition, the health functional food composition of the present invention may be manufactured into a food, particularly a functional food. The functional food of the present invention includes ingredients that are typically added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, and flavoring agents. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredients. The natural carbohydrate is preferably a monosaccharide (e.g., glucose, fructose, etc.), a disaccharide (e.g., maltose, sucrose, etc.), an oligosaccharide, a polysaccharide (e.g., dextrin, cyclodextrin, etc.), or a sugar alcohol (e.g., xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., taumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

[0050] In addition to the above health functional food composition, it may further contain various nutritional agents, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Although the proportion of these added ingredients is not of great importance, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health functional food composition of the present invention.

[0052] The present invention will be described in detail below by way of embodiments. However, the following embodiments are merely illustrative of the present invention, and the scope of the present invention is not limited to the following embodiments.

[0054] Example 1. Preparation of a biotransformation of Formononetin

[0055] (1) Culture of bacteria in various media compositions

[0056] The microorganism used for the biotransformation of formononetin was Bacillus siamensis ( Bacillus siamensisspp. BaoG-2-17) is the KCTC 15908BP strain, which was obtained from the Korean Collection for Type Culture (KCTC).

[0057] Bacillus siamensis strains were cultured for 16 hours at 30°C and 150 rpm in each medium composition disclosed in Table 1 below.

[0058] composition of experimental group media for bacterial culture experimental group Glucose (g / L) Tryptone (g / L) Yeast extract (g / L) 1 30 36.8179 10 2 2 10 5 3 30 20 10 4 30 3.18207 10 5 40 30 5 6 40 10 15 7 30 20 10 8 30 20 10 9 40 30 15 10 13.1821 20 10 11 46.8179 20 10 12 30 20 1.59104 13 30 20 10 14 20 30 50 15 20 10 15 16 40 10 5 17 20 30 15 18 30 20 18.409

[0060] (2) Induction of biorenovation reaction

[0061] Bacteria cultured under each culture condition were centrifuged at 4500g for 15 minutes at 4℃ to precipitate the pellet, and then washed twice with PG buffer (50mM Phosphate buffer, 2% Glycerin) to remove residual culture medium. The washed pellet was suspended in 100ml of PG buffer, and then 100mg of the substrate formononetin was added to induce a bioconversion reaction for 72 hours at 30℃ and 150rpm. After the reaction was completed, each supernatant was freeze-dried at -110℃, ground, and used for analysis.

[0063] (3) Analysis of the formation and conversion rate of formononetin biotransformations

[0064] HPLC (high performance liquid chromatography) analysis was performed on the biotransformed product prepared by the above method to analyze the presence and conversion rate of the biotransformed product.

[0065] As a result of confirming whether a formononetin biotransformer was produced, a novel peak not present in formononetin was identified, confirming that a formononetin derivative was produced from formononetin through the biotransformation method (Fig. 1A).

[0066] In addition, HPLC analysis compared the conversion rates according to culture medium conditions, and experimental group 4 showed the highest conversion efficiency at 88.7%, so the culture medium of experimental group 4 was determined to be the optimal condition for bioconversion (Fig. 1B).

[0068] (4) Isolation and identification of formononetin biotransformations

[0069] For the novel peaks generated from the formononetin derivatives of experimental group 4, the biotransformed compounds were identified through LC-MS (liquid chromatography-mass spectrometry) and NMR (nuclear magnetic resonance) analysis.

[0070] As a result, it was confirmed that the formononetin derivative was Formononetin 7-O-phosphate (FMP), in which the phenolic hydroxyl group (-OH) at the 7th position of formononetin was substituted with a phosphate group (-OPO3H2), and subsequent experiments were conducted using the sample (Fig. 1C).

[0072] Example 2. Effect of Formononetin Biotransformer on Inducing Proliferation of Human Hair Papillary Cells

[0073] To confirm the hair growth-promoting effect of the formononetin biotransformer, the viability of human dermal papilla cells (HDPCs) was checked. HDPC cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin in a humid incubator at 37°C and 5% CO2.

[0074] Cell viability was confirmed by MTT (3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) quantitative analysis. 1 × 10⁶ HDPC cells per well 4The cells were seeded into 96-well plates at a density of [number] and stabilized for 24 hours. Subsequently, the medium was removed and replaced with fresh medium free of FBS. Then, formononetin and formononetin biotransformants were treated at different concentrations (12.5 μM and 25 μM), respectively, and cultured for 24 hours. During this process, 25 μM minoxidil, which is effective in improving hair loss, was used as a positive control. Afterward, MTT solution was added and reacted for 2 hours to confirm the formation of purple formazan within the cells. The solution in each well was completely removed, and the formazan crystals were dissolved in DMSO; subsequently, the absorbance was measured at 570 nm using a microplate reader. Cell viability for each experimental group was expressed as a percentage relative to the control group.

[0075] As a result, as disclosed in Fig. 2, the proliferation of human hair papilla cells was significantly increased by treatment with the formononetin biotransformer (FMP) of the present invention compared to the untreated control group (None). In addition, it was confirmed that the human hair papilla cell proliferation induction effect of the formononetin biotransformer (FMP) treatment group of the present invention was superior to that of the formononetin treatment group (FM).

[0077] Example 3. Skin keratinocyte regeneration effect of formononetin biotransformer

[0078] To confirm the anti-hair loss effect of the formononetin biotransformer, a wound healing assay was performed on skin keratinocytes (HaCaT cells). HaCaT cells were cultured in DMEM medium containing 10% FBS and 1% penicillin / streptomycin in a humid incubator at 37°C under 5% CO2 conditions.

[0079] 1 × 10⁶ HaCaT cells per well 5The cells were dispensed into a 24-well plate at a density of [number] and stabilized for 24 hours. Subsequently, linear cells were removed by artificially creating physical damage (cell scratch) to the cell monolayer using a sterile pipette tip. Afterward, formononetin and formononetin biotransformants were treated at different concentrations (12.5 μM and 25 μM), respectively, and cultured for 24 hours. Immediately after cell removal, the scratch area was photographed under a microscope, and based on this, the degree of cell proliferation at the edge of the scratch was observed after 24 hours.

[0080] As a result of analyzing cell proliferation based on the scratch area of ​​cells 24 hours after treatment with formononetin and formononetin biotransformer, the formononetin-treated group (FM) did not show a significant effect on cell proliferation compared to the untreated control group (None). On the other hand, in the formononetin biotransformer-treated group of the present invention (FMP), cell proliferation at the wound site increased significantly in a concentration-dependent manner, and it was confirmed that cells proliferated faster than the untreated control group (Fig. 3).

[0081] Through these results, it was confirmed that the formononetin biotransformer of the present invention promotes the proliferation and wound healing of skin cells, and exhibits effects of protecting scalp cells and strengthening the skin barrier, making it a useful substance for preventing hair loss.

Claims

Claim 1 A cosmetic composition for promoting hair growth or preventing hair loss, containing formononetin 7-O-phosphate of the following Chemical Formula 2 or a cosmetically acceptable salt thereof as an active ingredient. [Chemical Formula 2] Claim 2 delete Claim 3 In claim 1, the formononetin 7-O-phosphate (1) is Bacillus siamensis ( Bacillus siamensis A cosmetic composition for promoting hair growth or preventing hair loss, characterized by comprising the steps of: (1) culturing a strain in a medium containing 25-35 g / L glucose, 2-4 g / L tryptone, and 8-12 g / L yeast extract at 25-35°C for 12-20 hours; (2) adding formononetin to the Bacillus siamensis strain cultured in step (1) to induce a biotransformation reaction at 25-35°C for 60-80 hours; and (3) freeze-drying and then grinding the formononetin biotransformation product obtained in step (2). Claim 4 A cosmetic composition for promoting hair growth or preventing hair loss according to claim 1, wherein the formononetin 7-O-phosphate or a cosmetically acceptable salt thereof promotes the growth of hair papilla cells. Claim 5 A quasi-drug for promoting hair growth or preventing hair loss containing formononetin 7-O-phosphate of the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient.[Chemical Formula 2] Claim 6 A pharmaceutical composition for preventing hair loss or promoting hair growth, containing formononetin 7-O-phosphate of the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula 2] Claim 7 A pharmaceutical composition for preventing hair loss or promoting hair growth according to claim 6, characterized in that the composition is prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols. Claim 8 A health functional food composition for promoting hair growth or preventing hair loss, containing formononetin 7-O-phosphate of the following Chemical Formula 2 or a food-acceptable salt thereof as an active ingredient. [Chemical Formula 2] Claim 9 A health functional food composition for promoting hair growth or preventing hair loss according to claim 8, characterized in that the composition is manufactured in any one formulation selected from powder, granules, pills, tablets, capsules, candies, syrups, and beverages.

Images